Prevention of autoimmune diabetes in non-obese diabetic mice by treatment with a class II major histocompatibility complex-blocking peptide by unknown
Brief Definitive  Report 
Prevention of Autoimmune Diabetes in Non-Obese 
Diabetic Mice by Treatment with a Class II Major 
Histocompatibility  Complex-blocking Peptide 
By Ursula Hurtenbach, Eduard Lier, Luciano Adorini, 
and Zoltan A. Nagy* 
From the Preclinical Research, Sandoz Pharma Ltd., 4002 Basel, Switzerland; and the 
*Department of lnflammation/Autoimmune Diseases, Hoffmann-La Roche Inc., Nutley, 
New Jersey 07110 
Summary 
The role of antigen presentation  as a possible mechanism underlying major histocompatibility 
complex (MHC) association of autoimmune disease has been studied in non-obese diabetic (NOD) 
mice. By screening for inhibition  of antigen presentation  to NOD T  cell hybridoma, we have 
selected a synthetic peptide, yTYTVHAAHAYTYt  (small letters denote D  amino acids), that 
efficiently blocks antigen presentation by the NOD class II MHC molecule AoegTA/3g  7 (As  7) in 
vitro.  The inhibition  is MHC selective,  in that  it does not affect antigen  presentation  by the 
E d and E k molecules, and has only a marginal effect on presentation by the A d molecule. This 
peptide also inhibits  the priming  for As7-restricted T  cell responses in vivo, and prevents the 
spontaneous development of diabetes in female NOD mice, when administered chronically from 
3 wk of age on.  Chronic  treatment  with a control peptide, KMKMVHAAHAKMKM,  that 
fails to bind to Ag  7 has  no effect on the disease.  These data indicate that antigen presentation 
by the As  7 molecule plays a pivotal role in the induction of autoimmune diabetes. Furthermore, 
the results demonstrate  that  interference with antigen  presentation  by a class II molecule can 
prevent  the onset of spontaneous  autoimmune  disease associated with  the  same molecule. 
S 
usceptibility to autoimmune  diseases  is associated with 
certain class I or II alleles of the MHC (1). Similarly,  an- 
imal  models  of autoimmune  diseases  often exhibit  MHC 
linkage (2-6). Recently, two sets of findings have shed light 
on the, thus far enigmatic, mechanisms underlying MHC--dis- 
ease association. First, MHC molecules have been shown to 
possess a binding site capable of interacting  with antigenic 
peptides  in  an  allele-dependent,  selective  manner  (7-10). 
Second, the intramolecular mapping of MHC--disease linkages 
has revealed that in certain instances susceptibility or resis- 
tance  depends  on  particular  amino  acid  residues  localized 
within the peptide-binding site (11-14). Thus, the most likely 
explanation for MHC-disease association would be that the 
disease-inducing autoantigen  is selectively presented by the 
particular allelic form of MHC molecule that confers disease 
susceptibility (15).  Since, however, the antigens involved in 
most autoimmune diseases  are unknown,  this hypothesis is 
not directly testable.  Here, we have taken the approach of 
MHC blockade (16--18) to test the above hypothesis experimen- 
tally. Using the non-obese diabetic (NOD) mouse as an au- 
toimmune disease model (19), we demonstrate that a peptide 
capable of blocking antigen presentation by the NOD class 
II MHC molecule As  7,  in vitro and in vivo, can also pre- 
vent the spontaneous development of type I diabetes linked 
to this class  II molecule (6). 
Materials and Methods 
Mice.  NOD mice, originally derived from Dr. E. Leiter's colony 
(The Jackson Laboratory, Bar Harbor, ME), were bred under specific 
pathogen-free conditions in the Sandoz animal facilities. Diabetes 
occurs in 65-72% of female and 15-24% of male mice in this colony. 
Treatment of  NOD Mice with Peptides.  To inhibit in vivo priming 
for T cell responses, 500 nmol of peptide in HBSS was injected 
subcutaneously into the flanks of mice daily for 4 d. The immunogen 
was injected into the hind footpads in CFA on day 2 of peptide 
treatment.  To prevent diabetes, mice were injected with 500 nmol 
of peptide daily, intraperitoneally and subcutaneously, at multiple 
sites. Mice were treated from 3 to 23 wk of age with decreasing 
frequency of injections as described in Results. Groups of mice in- 
jected with HBSS (solvent) were included to control for stress effect. 
To prevent peptide-induced hypersensitivity symptoms, chronically 
treated mice received 3 mg/kg of 4-(1-methyl-4-piperidylidene)- 
4H-benzo(4,5)cyclohepta(1,2-b)thiophen-10(9H)-lH  fumarate (keto- 
tifen; Zaditen; Sandoz, Basel, Switzerland; reference 20), injected 
together with the peptide for the last 2 wk of treatment. 
T  Cell Hybridoma.  Hybridomas 2D12.1, 2G7.1, and 1Hll.3 
were generated by fusing hen egg white lysozyme (HEL)-immune 
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thymoma as described previously (21). Fine specificity of the hy- 
bridoma was determined by response to a panel of overlapping HEL 
peptides in the presence of APC (21; and L. Adorini, unpublished 
results). Peptide competition for antigen presentation was tested 
by incubating 2.5  x  10  s NOD splenocytes or 2.5  x  104 LK cells 
per well as APC, with antigenic and competitor peptides (as shown 
in Fig. 1), in 96-weU flat-bottomed microtiter plates for 24 h. Cul- 
ture medium was KPMI 1640 supplemented with 10% FCS. The 
cells were then irradiated (2,000 tad) and washed before adding 
5  x  104 hybridoma cells per well (in 0.2 ml). After 24 h of cul- 
ture, 50-#1 aliquots of supernatant were transferred to microcul- 
ture wells containing 104 CTLL cells. II,-2 production was assessed 
by thymidine incorporation into CTLL during the last 4 h of the 
24-h culture. 
Peptides.  Peptides were prepared by the solid phase method and 
purified as described previously (17). 
ELISA  Methods.  Peptide-specific  antibodies were detected by 
the ELISA method. Microtiter wells were coated with 250 ng pep- 
tide in 50/~1 PBS at 4~  overnight. The plates were then washed 
four times with PBS/0.2% Tween 20, and blocked with 2% BSA 
in PBS at 37~  for 30 min. After washing twice in PBS/Tween 
20 and four times in PBS, the plates were incubated with 50/~l/well 
of the test sera, diluted in PBS  +  1% BSA  +  0.2% Tween 20, 
at  37~  for  1  h.  Subsequently,  the  plates  were washed  with 
PBS/Tween 20, and incubated with either phosphatase-coupled goat 
anti-mouse Ig, anti-IgG, or anti-IgM (Southern Biotechnology As- 
sociates, Inc., Birmingham, AL), each at 1:500 dilution, at 37~ 
for 2 h.  After washing,  100/~l/well of p-nitrophenyl-phosphate 
disodium (1 mg/ml) was added and incubation followed for 45 rain. 
Color reaction was measured in an ELISA counter (Titertek, Dyna- 
tech Labs, Inc., Chantilly, VA) at OD 405 nm. Background (test 
sera in uncoated wells) was subtracted from the mean of duplicate 
OD values. Serum IgE was measured as described (22). IgE deter- 
minations were performed by Dr. C. Heusser (Ciba-Geigy Inc., 
Basel,  Switzerland). 
Results 
To identify peptides that block antigen presentation by the 
As  7 molecule, we screened a panel of peptides for inhibition 
of Ag?-restricted antigen presentation to T  cell hybridoma. 
Since NOD  mice were found to give a strong AgT-restricted 
T  cell response to HEL peptide 8-29  (L.  Adorini,  unpub- 
lished observation) and to sheep insuline (23), hybridoma of 
these two specificities were produced for peptide screening. 
Because of the  similarity between  the  A d and  Ag  ? class  II 
molecules (24), peptides known to bind to the A d molecule 
(25) were included in the panel. Based on the screening results, 
we selected for further studies one peptide that binds  (Pl, 
yTYTVHAAHAYTYt, in one-letter code; small letters de- 
note D  amino acids; 25) and another that fails to bind (P2, 
KMKMVHAAHAKMKM;  25) to As  7. The effect of these 
two peptides on antigen presentation by four different class 
II molecules is shown in Fig. 1. P1 inhibited the presentation 
of HEL 8-29 by As  v strongly (IC50,  ~1/~M),  that of OVA 
323-339 by A d weakly (ICs0,  ,,020 #M),  and had no effect 
on  the  presentation  of either  HEL  1-18  by  E k  or  HEL 
105-120 by E a. P2 inhibited antigen presentation by A d and 
E k, but  not that by As  7 and E a.  Thus,  both peptides have 
satisfied the specificity criteria for a selective MHC blocker. 
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Figure  1.  Selective  inhibition of antigen presentation  by Pl (diamonds) 
and P2 (triangles). Results represent antigen-induced II.,2 production by 
T cell hybridoma (100% is the response in the absence of Pl or P2). (A) 
APC, NOD splenocytes;  antigen, 80 nM of HEL 8-29; hybridoma, 2D12.1 
specific for HEL 8-29 presented by AsT; 100% is 191,682 cpm; back- 
ground (IL-2 production in the absence of antigen) is 266 cpm. (B) APC, 
LK lymphoma  cells; antigen, 1/~M of OVA 323-339; hybridoma, DOl1.10 
specific for OVA 323-339 on Ad; 100% is 40,287 cpm; background is 
1,895 cpm. (C) APC, LK cells; antigen, 2/~M of HEL 1-18; hybridoma, 
2G7.1 specific for HEL 1-18 on Ek; 100% is 117,150 cpm; background 
is 296 cpm. (D) APC, LK cells; antigen, 500 nM of HEL 105-120; hy- 
bridoma, 1Hll.3 specific  for HEL 105-120 on Ed; 100% is 281.444 cpm; 
background is 775 cpm. 
P2 was shown by Lamont et al. (25, 26) to be relatively resis- 
tant to proteases, in vitro and in vivo, and P1 was rendered 
similarly resistant by including D  amino acids at the NH2 
and  COOH  termini. 
Since we planned to use Pl for prevention of diabetes,  it 
was important to ascertain that this peptide was suitable for 
chronic treatment, i.e., it exhibited immunosuppressive effect 
when applied in soluble form (18). We therefore tested whether 
P1 administered in isotonic aqueous solution could interfere, 
in vivo, with the induction of Ag7-restricted T  cell responses. 
Mice were injected daily with 500 nmol of Pl for 4 d, and 
immunized  on day 2  of treatment  with  10 nmol  of OVA 
323-335 or HEL 8-29 in CFA. 9 d after immunization, the 
draining lymph nodes were removed, and antigen-specific T 
cell proliferation was determined (17). The representative ex- 
periment in Fig.  2 demonstrates a substantial  inhibition of 
T  cell response to OVA 323-335 in Pl-treated mice, in corn- 
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Figure 2.  In vivo inhibition  of T cell priming to OVA 323-335 by Pl. 
The data represent antigen-specific proliferation of T cells from draining 
lymph nodes explanted 9 d after immunization. OVA 323-335-specific 
proliferation  of lymph node cells from NOD mice treated with P1 (tri- 
angles)  or solvent only (squares),  as described in Materials and Methods, 
is shown.  Curves represent the response of individual mice. 
parison with the controls treated with the solvent only. A 
similar treatment with P2 had no immunosuppressive effect 
(data not shown). P1 also inhibited T cell priming to HEL 
8-29 (data not shown). 
It was then investigated whether a chronic treatment of 
prediabetic NOD mice with P1 would interfere with the de- 
velopment of diabetes. The treatment schedule was based on 
the observation that young NOD mice develop lymphocytic 
infiltration  in the islets of Langerhans from the age of 3-4 
wk (27). Thus, T cell recognition of a putative self-antigen 
presented by the As7 molecule could occur from this age on. 
We therefore treated 3-wk-old NOD mice with 500 nmol 
of the As7 blocker P1 five times per week for 3 wk, followed 
by 500 nmol five times per week for 3 wk, and 500 nmol 
twice a week until the age of 22-23 wk.  Control groups 
of animals were treated either with the nonblocking peptide 
P2, or with solvent only. In the first experiment (Fig. 3 A), 
the Pl-treated group of mice did not develop diabetes until 
16 wk of age, and thereafter, the frequency of diabetic animals 
did not exceed 16% for the whole period of treatment. In 
the control groups,  diabetes onset was between 13 and 16 
wk of age, and the plateau level of 60% diabetic animals was 
reached by 22 wk of age. By Fisher's exact test, the diabetes 
incidence at 22 wk of age was significantly different between 
the Pl- and P2-treated group (p  =  0.036), and between the 
P1- and solvent-treated  group (,p  =  0.025).  The variation 
of diabetes onset observed in the control groups reflects most 
likely family differences that occur within the same NOD 
colony (U. Hurtenbach, unpublished observation). After the 
cessation of P1 treatment at week 22, the frequency of dia- 
betic animals increased in parallel with the control groups. 
In this experiment, mortality occurred in both peptide-treated 
groups (6/18 Pl-treated and 1/12 P2-treated mice died) after 
10-18 wk of treatment, preceded by symptoms of peptide- 
induced immediate-type hypersensitivity  (28), such as lack 
of movement upon prompting, shallow breathing, and pros- 
trate posture. In the second experiment (Fig. 3 B), the mice 
received  P1  mixed  with  an  antianaphylactic  compound 
(ketotifen) after showing the first signs of postinjection  fa- 
tigue (after 20 wk of treatment). This group of mice did 
not develop diabetes until the end of treatment, furthermore, 
the mice remained symptomless, and no mortality occurred. 
Treatment with ketotifen alone had no influence on the dis- 
ease. Thus, treatment with the As  7 blocker P1 resulted in 
a delayed  onset and a significantly  decreased  frequency or com- 
plete absence of diabetes. 
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Figure 3.  Prevention of spontaneous autoimmune di- 
abetes in NOD mice by Pl. (A) Groups of female mice 
were treated from 3 to 22 wk of age with P1 (18 mice; 
diamonds),  P2 (12 mice; inverted triangles),  or solvent only 
(18 mice; triangles).  (13) Mice were treated with P1 for 20 
wk  followed by  Pl  supplemented  with  3  mg/kg  of 
ketotifen until 23 wk of age (13 mice; diamonds),  ketotifen 
only (15 mice; squares),  or solvent only (15 mice; triangles). 
Arrows indicate the cessation of treatment. Diabetes inci- 
dence was monitored from 10 wk of age. Mice with at 
least 200 mg/dl of glucose in blood were considered dia- 
betic. The number of diabetic per total mice is shown for 
each group (except where 0) at each time point of deter- 
mination. 
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bound to MHC molecules, class II MHC-blocking peptides 
are expected to induce immunity against  themselves unless 
they are under self-tolerance  (17) or rendered  nonimmuno- 
genic. Immune responses  against  MHC blockers could lead 
to accelerated elimination and thereby  decreased efficacy of 
these substances,  as well as to diverse side effects, such as the 
immediate hypersensitivity observed in this study.  Previous 
results have shown that a single dose of class II-blocking pep- 
tides, when applied in soluble form, fails to induce a prolifer- 
ative T cell response (18). However, the immunogenicity of 
chronically applied,  soluble MHC-binding peptides has not 
yet been assessed. We therefore tested whether long-term treat- 
ment of NOD mice with P1 and P2 (from Fig. 3 A) would 
lead to immunization against these peptides. The data in Fig. 
4 demonstrate the presence of antibodies in the sera of both 
groups of peptide-treated mice.  Antibodies were detectable 
up to a serum dilution of 1:200, i.e., their titer was low. Mice 
treated with the class II-binding  Pl produced IgG but  no 
IgM antibodies.  The number of antibody-positive mice in- 
creased with the duration of treatment.  However, approxi- 
mately half of this group remained  antibody negative after 
13 wk of treatment. Interestingly,  mice treated with the non- 
binding P2 peptide also mounted an antibody response, which 
was exclusively of IgM isotype.  Approximately  half of the 
mice were also nonresponders in this group. The isotype differ- 
ence of P1- and P2-specific antibodies probably reflects  the 
presence and absence, respectively,  of class II-restricted T cell 
help in these responses.  In the experiment in Fig. 3 B, only 
3 of 13 Pl-treated animals  produced antibodies against  the 
peptide (data not shown). Thus, chronic application of soluble 
peptides can induce a low titer IgM or IgG antibody response, 
although the majority of treated  animals  may remain non- 
responder.  In view of the observed hypersensitivity  symp- 
toms, we also determined serum IgE levels and found a sub- 
stantial elevation in mice treated with Pl (8.29  _+ 2.7 #g/ml) 
or P2 (6.9  _+ 3.76/~g/ml),  over the solvent-treated (1.78  _+ 
1.67/zg/ml) or untreated (0.68  +_ 0.85/zg/ml) animals. These 
data  suggest  that IgE antibodies  against  the peptides  may 
be responsible for the observed immediate  hypersensitivity 
reactions. 
Discussion 
The data presented  herein  demonstrate  a correlation be- 
tween the capacity of a peptide to block antigen presentation 
by the As  v molecule in vitro,  to inhibit the priming for As  7- 
restricted  T cell responses  in vivo, and to interfere with the 
development of spontaneous autoimmune diabetes in NOD 
mice. Since the development of diabetes is genetically linked 
to the As  7 class II allele (6), the data provide  support for the 
hypothesis that the mechanism underlying disease linkage to 
a particular  class  II  allele  is  the presentation  of a disease- 
inducing  antigen  by  the  molecule  encoded by  this  allele. 
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Figure  4.  Antibody response of 
NOD mice after chronic treatment 
with Pl (top) and P2 (bottom).  IgG 
antibodies  to Pl and IgM to P2 are 
shown (Pl induced no IgM and P2 
no IgG antibodies; data not shown). 
Each triangle represents antibodies 
of an individual mouse at the time 
point and serum dilution indicated. 
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peptides can selectively inhibit the induction of T  cell re- 
sponses  to other peptides binding to the same MHC mole- 
cule (17,  18). These findings have been extended to an au- 
toimmune disease model, namely experimental autoimmune 
encephalomyelitis (EAE). Thus, EAE induced by peptides of 
myelin basic protein can be prevented by peptides competing 
with the pathogenic ones for the same class II MHC-binding 
sites  (26,  29,  30).  Since the antigens involved in most au- 
toimmune diseases are unknown, the MHC molecule that 
presents putative disease-inducing antigens is, at present, the 
only target available for selective immunosuppressive inter- 
vention. Our data demonstrate the feasibility of an MHC- 
binding site-directed immunosuppressive approach, for the 
first time, in a spontaneously occurring, MHC-linked autoim- 
mune disease model. It should be pointed out that the patho- 
genesis of NOD diabetes, similarly to human type I diabetes, 
commences with lymphocytic infiltration of the islets of Lang- 
erhans at young age, followed by selective depletion of the 
insulin-producing/3 cells (19). Furthermore, the first domain 
of the As  7/3 chain exhibits sequence homology with the DQ 
/3 chains conferring susceptibility to type I diabetes in humans 
(11, 24).  Thus, the close resemblance of the NOD disease 
model to a human autoimmune disease raises the possibility 
that the immunosuppressive principle applicable in this model 
may also be effective  in human autoimmune conditions. Our 
data also suggest that MHC blocking may not permanently 
suppress  disease, that is, the symptoms can return after the 
cessation of treatment. Thus,  a continuous treatment may 
be necessary, or alternatively, this immunosuppressive strategy 
may preferentially be applied in diseases occurring as episodes 
interrupted by symptom-free periods, e.g., rheumatoid ar- 
thritis and multiple sclerosis. An important observation in 
this study is that peptides, although not immunogenic when 
applied short term in soluble form (18), can induce antibody 
production and severe immunological side effects in a frac- 
tion of animals upon long-term treatment. Thus, although 
14 residue-long peptides proved to be suitable reagents for 
testing the validity of MHC blockade as an immunosuppres- 
five strategy, they will probably not become suitable drugs. 
Therefore, the pharmacological application of this strategy 
should solve the problem of immunogenicity, perhaps by the 
development of smaller, possibly nonpeptidic MHC-blocking 
molecules. 
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